| UniProt ID | BPHL_HUMAN | |
|---|---|---|
| UniProt AC | Q86WA6 | |
| Protein Name | Valacyclovir hydrolase | |
| Gene Name | BPHL | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 291 | |
| Subcellular Localization | ||
| Protein Description | Serine hydrolase that catalyzes the hydrolytic activation of amino acid ester prodrugs of nucleoside analogs such as valacyclovir and valganciclovir. Activates valacyclovir to acyclovir. May play a role in detoxification processes. It is a specific alpha-amino acid ester hydrolase that prefers small, hydrophobic, and aromatic side chains and does not have a stringent requirement for the leaving group other than preferring a primary alcohol.. | |
| Protein Sequence | MVAVLGGRGVLRLRLLLSALKPGIHVPRAGPAAAFGTSVTSAKVAVNGVQLHYQQTGEGDHAVLLLPGMLGSGETDFGPQLKNLNKKLFTVVAWDPRGYGHSRPPDRDFPADFFERDAKDAVDLMKALKFKKVSLLGWSDGGITALIAAAKYPSYIHKMVIWGANAYVTDEDSMIYEGIRDVSKWSERTRKPLEALYGYDYFARTCEKWVDGIRQFKHLPDGNICRHLLPRVQCPALIVHGEKDPLVPRFHADFIHKHVKGSRLHLMPEGKHNLHLRFADEFNKLAEDFLQ | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 18 | Phosphorylation | LRLRLLLSALKPGIH HHHHHHHHHHCCCCC | 31.37 | - | |
| 70 (in isoform 2) | Ubiquitination | - | 6.47 | 21890473 | |
| 86 | Acetylation | PQLKNLNKKLFTVVA HHHHHHCCCEEEEEE | 54.76 | - | |
| 87 | Ubiquitination | QLKNLNKKLFTVVAW HHHHHCCCEEEEEEE | 48.00 | 21890473 | |
| 87 (in isoform 1) | Ubiquitination | - | 48.00 | 21890473 | |
| 119 | Acetylation | DFFERDAKDAVDLMK HHHHCCHHHHHHHHH | 50.97 | - | |
| 126 | Acetylation | KDAVDLMKALKFKKV HHHHHHHHHHCCCEE | 58.84 | 19608861 | |
| 126 | Succinylation | KDAVDLMKALKFKKV HHHHHHHHHHCCCEE | 58.84 | - | |
| 126 | Succinylation | KDAVDLMKALKFKKV HHHHHHHHHHCCCEE | 58.84 | - | |
| 126 | Malonylation | KDAVDLMKALKFKKV HHHHHHHHHHCCCEE | 58.84 | 26320211 | |
| 126 | 2-Hydroxyisobutyrylation | KDAVDLMKALKFKKV HHHHHHHHHHCCCEE | 58.84 | - | |
| 131 | Acetylation | LMKALKFKKVSLLGW HHHHHCCCEEEEEEE | 51.16 | 30587215 | |
| 132 | Acetylation | MKALKFKKVSLLGWS HHHHCCCEEEEEEEC | 39.94 | 30587221 | |
| 151 | Acetylation | TALIAAAKYPSYIHK HHHHHHHHCCHHHHC | 53.63 | 25038526 | |
| 154 | Phosphorylation | IAAAKYPSYIHKMVI HHHHHCCHHHHCHHH | 33.36 | 22210691 | |
| 167 | Phosphorylation | VIWGANAYVTDEDSM HHCCCCEEECCCCHH | 12.04 | 22210691 | |
| 169 | Phosphorylation | WGANAYVTDEDSMIY CCCCEEECCCCHHHH | 22.46 | 22210691 | |
| 174 (in isoform 2) | Ubiquitination | - | 6.14 | 21890473 | |
| 183 | Phosphorylation | YEGIRDVSKWSERTR HHHCCCHHHHCHHHC | 32.47 | - | |
| 184 | Succinylation | EGIRDVSKWSERTRK HHCCCHHHHCHHHCC | 55.37 | - | |
| 184 | Succinylation | EGIRDVSKWSERTRK HHCCCHHHHCHHHCC | 55.37 | - | |
| 186 | Phosphorylation | IRDVSKWSERTRKPL CCCHHHHCHHHCCHH | 22.42 | 28857561 | |
| 191 (in isoform 1) | Ubiquitination | - | 54.03 | 21890473 | |
| 191 | Acetylation | KWSERTRKPLEALYG HHCHHHCCHHHHHHC | 54.03 | 66723391 | |
| 191 | Succinylation | KWSERTRKPLEALYG HHCHHHCCHHHHHHC | 54.03 | - | |
| 191 | Succinylation | KWSERTRKPLEALYG HHCHHHCCHHHHHHC | 54.03 | 27452117 | |
| 191 | Ubiquitination | KWSERTRKPLEALYG HHCHHHCCHHHHHHC | 54.03 | 21890473 | |
| 217 | Malonylation | VDGIRQFKHLPDGNI HHHHHHCCCCCCCCH | 35.57 | 32601280 | |
| 217 | Acetylation | VDGIRQFKHLPDGNI HHHHHHCCCCCCCCH | 35.57 | 25953088 | |
| 243 | 2-Hydroxyisobutyrylation | ALIVHGEKDPLVPRF EEEECCCCCCCCCCC | 70.05 | - | |
| 243 | Acetylation | ALIVHGEKDPLVPRF EEEECCCCCCCCCCC | 70.05 | 25038526 | |
| 243 | Succinylation | ALIVHGEKDPLVPRF EEEECCCCCCCCCCC | 70.05 | 27452117 | |
| 257 | Malonylation | FHADFIHKHVKGSRL CCHHHHHHHCCCCCE | 45.32 | 26320211 | |
| 257 | Acetylation | FHADFIHKHVKGSRL CCHHHHHHHCCCCCE | 45.32 | 23954790 | |
| 257 | Ubiquitination | FHADFIHKHVKGSRL CCHHHHHHHCCCCCE | 45.32 | - | |
| 260 | Acetylation | DFIHKHVKGSRLHLM HHHHHHCCCCCEEEC | 51.38 | 2403327 | |
| 260 | Succinylation | DFIHKHVKGSRLHLM HHHHHHCCCCCEEEC | 51.38 | - | |
| 260 | Succinylation | DFIHKHVKGSRLHLM HHHHHHCCCCCEEEC | 51.38 | - | |
| 271 | Malonylation | LHLMPEGKHNLHLRF EEECCCCCCCCHHHC | 27.88 | 26320211 | |
| 271 | Succinylation | LHLMPEGKHNLHLRF EEECCCCCCCCHHHC | 27.88 | - | |
| 271 | Succinylation | LHLMPEGKHNLHLRF EEECCCCCCCCHHHC | 27.88 | - | |
| 271 | Acetylation | LHLMPEGKHNLHLRF EEECCCCCCCCHHHC | 27.88 | 25825284 | |
| 277 | Methylation | GKHNLHLRFADEFNK CCCCCHHHCHHHHHH | 17.60 | - | |
| 284 | Acetylation | RFADEFNKLAEDFLQ HCHHHHHHHHHHHHC | 55.16 | 25038526 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of BPHL_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of BPHL_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of BPHL_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| MUTA_HUMAN | MUT | physical | 26186194 | |
| SETD3_HUMAN | SETD3 | physical | 26186194 | |
| PPP5_HUMAN | PPP5C | physical | 26186194 | |
| TTC19_HUMAN | TTC19 | physical | 26186194 | |
| C1TM_HUMAN | MTHFD1L | physical | 26344197 | |
| SETD3_HUMAN | SETD3 | physical | 28514442 | |
| TTC19_HUMAN | TTC19 | physical | 28514442 | |
| PPP5_HUMAN | PPP5C | physical | 28514442 | |
| CH60_HUMAN | HSPD1 | physical | 28514442 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Acetylation | |
| Reference | PubMed |
| "Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-126 AND LYS-257, AND MASSSPECTROMETRY. | |